Participants must have completed 3 cycles of a bortezomib-based induction regimen (as defined by current NCCN guidelines) and have no evidence of disease progression as defined by IMWG criteria.
Participants with light chain and free light chain (FLC) only may be enrolled if they meet all the criteria for a diagnosis of MM.
Participants must be considered by their physician eligible to receiving the IRD regimen.
Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2 at time of enrollment.

NCT03173092_inc_T1
Multiplier
3 cycles
NCT03173092_inc_T2
Drug
bortezomib
NCT03173092_inc_T3
Procedure
induction regimen
NCT03173092_inc_T4
Qualifier
NCCN guidelines
NCT03173092_inc_T5
Value
no evidence of disease progression
NCT03173092_inc_T6
Measurement
IMWG criteria
NCT03173092_inc_T7
Measurement
criteria for a diagnosis of MM
NCT03173092_inc_T8
Value
all
NCT03173092_inc_T9
Condition
light chain and free light chain (FLC)
NCT03173092_inc_T10
Mood
eligible to
NCT03173092_inc_T11
Procedure
IRD regimen
NCT03173092_inc_T12
Measurement
Eastern Cooperative Oncology Group (ECOG) performance status
NCT03173092_inc_T13
Value
0, 1, or 2
NCT03173092_inc_T14
Temporal
at time of enrollment